证券代码：301267 证券简称：华厦眼科 公告编号：2025-027 华厦眼科医院集团股份有限公司 关于取消监事会、修订《公司章程》及制定、修订、废止部分制度 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召 开了第三届董事会第十次会议，审议通过了《关于取消监事会、修订<公司章程>及 制定、修订、废止部分制度的议案》，并同意将该议案中的部分子议案提交公司股 东会审议。现将有关事项公告如下： 一、修订《公司章程》部分条款的相关情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司章 程指引》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等法律、法规和规范性文件的最新 规定，结合公司实际情况，公司拟对《公司章程》部分条款进行修订。本次《公司 章程》修订完成后，公司将不再设置监事会和监事，监事会的职权由董事会审计委 员会行使。 | 修订前 | 修订后 | | --- | --- | | 第 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2025-029 华厦眼科医院集团股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开了第三届董事会第十次会议，决定于 2025 年 9 月 10 日（星期三）召开公 司 2025 年第一次临时股东会，本次股东会采用现场表决与网络投票相结合的方 式召开，现将本次会议的有关事项通知如下： 一、召开会议的基本情况 1、会议届次：2025 年第一次临时股东会 2、会议召集人：公司董事会 （1）现场会议时间：2025 年 9 月 10 日（星期三）下午 15:00； （2）网络投票时间：2025 年 9 月 10 日； 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 10 日 9:15-9:25、9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 9 月 10 日 9:15-15:00。 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2025-023 华厦眼科医院集团股份有限公司 第三届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日上午以现场会议与通讯会议相结合的方式在公司会议室召开第三届监事会第 十次会议，会议通知于 2025 年 8 月 11 日以电子邮件和即时通讯的方式送达。 本次会议应出席监事 3 名，实际出席监事 3 名。本次会议由监事会主席黄妮娅 女士主持，会议的召集、召开符合《中华人民共和国公司法》《公司章程》等 有关规定。 二、监事会会议审议情况 全体与会监事以投票表决方式审议通过以下议案： 1、审议通过《关于<2025 年半年度报告>及其摘要的议案》 表决结果：同意 3 票；反对 0 票；弃权 0 票。 公司全体监事签署书面确认意见，保证公司《2025 年半年度报告》及其摘 要内容真实、准确、完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：同意 3 票；反对 0 票；弃权 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2025-022 华厦眼科医院集团股份有限公司 第三届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日上午以现场会议与通讯会议相结合的方式在公司会议室召开第三届董事会第 十次会议，会议通知于 2025 年 8 月 11 日以电子邮件和即时通讯的方式送达。 本次会议应出席董事 7 名，实际出席董事 7 名（其中：委托出席董事 1 名，董 事苏庆灿先生因个人原因无法亲自出席会议，委托董事陈凤国先生出席会议并 代为行使表决权）；公司监事和高管列席了本次会议。经全体参会董事一致推 举，本次会议由董事陈凤国先生主持，会议的召集、召开符合《中华人民共和 国公司法》《公司章程》等有关规定。 二、董事会会议审议情况 全体与会董事以投票表决方式审议通过以下议案： 表决结果：同意7票；反对0票；弃权0票。 该议案已经公司董事会审计委员会审议通过。 上述具体内容详见公司同日发布于巨潮资讯网（www. ...

华厦眼科8月24日披露半年报，公司上半年实现营业收入21.39亿元，同比增长4.31%；归属于上市公司 股东的净利润2.82亿元，同比增长6.20%；基本每股收益0.34元。 ...

华厦眼科医院集团股份有限公司 2025 年半年度报告全文 华厦眼科医院集团股份有限公司 2025 年半年度报告 2025 年 8 月 1 华厦眼科医院集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人苏庆灿、主管会计工作负责人陈凤国及会计机构负责人(会计 主管人员)陈鹭燕声明：保证本半年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次半年报的董事会会议： | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | | 苏庆灿 | 董事长 | 因个人原因 | 陈凤国 | 本报告涉及未来发展规划和经营计划等前瞻性描述不构成公司对投资者的 实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理 解规划、计划、预测与承诺之间的差异。敬请投资者注意投资风险。 报告期内，公司主营业务、核心竞争力、主要财务指 ...

Group 1: Core Insights - The report highlights a strong performance in the pharmaceutical and biotechnology sector, with an overall increase of 3.08% from August 11 to August 15, 2025, outperforming the CSI 300 index by 0.71 percentage points [5][6] - Year-to-date, the pharmaceutical and biotechnology sector has risen by 25.02%, ranking fourth among 31 industries, and surpassing the CSI 300 index by 18.22 percentage points [5][6] - The current PE valuation for the pharmaceutical and biotechnology sector stands at 31.31 times, which is at the historical median level, with a premium of 145% compared to the CSI 300 index [5][6] Group 2: Industry Developments - The National Healthcare Security Administration (NHSA) announced the preliminary review list for the 2025 National Basic Medical Insurance and commercial insurance drug directories, with 534 drugs passing the basic medical insurance review and 121 passing the commercial insurance review [6][7] - The NHSA issued a temporary management method for disease-based payment, aimed at addressing issues such as dynamic adjustment expectations and regional management disparities [6][7] - Novo Nordisk received FDA approval for a supplemental new drug application for semaglutide (Wegovy) to treat patients with metabolic dysfunction-associated fatty liver disease [7] Group 3: Investment Recommendations - The report suggests that the pharmaceutical and biotechnology sector is expected to continue its upward trend, driven by the recent announcements from the NHSA regarding drug directory updates and payment management reforms [7] - It is recommended to focus on investment opportunities in innovative drugs, CXO, medical devices, traditional Chinese medicine, chain pharmacies, and medical services as the market enters a period of intensive mid-year report disclosures [7][9] - A specific stock recommendation list includes companies such as Betta Pharmaceuticals, Teva Biologics, and Kaili Medical, with a watchlist including Kelun Pharmaceutical and Qianhong Pharmaceutical [9]

Company Overview - Huaxia Eye Hospital Group Co., Ltd. specializes in ophthalmology services, with key offerings including cataract projects, posterior segment projects, refractive projects, and comprehensive optometry projects [1] - As of the first quarter of 2025, the company reported revenue of 1.093 billion yuan, representing a year-on-year increase of 11.74%, while net profit was 150 million yuan, showing a year-on-year decrease of 4.00% [1] Financial Metrics - The company's closing stock price on August 15 was 20.67 yuan, with a PE ratio of 41.11 times and a total market capitalization of 17.363 billion yuan [1] - The average PE ratio for the healthcare services industry is 49.76 times, with a median of 64.18 times, placing Huaxia Eye Hospital at the 26th position within the industry [1][2] - The company has a sales gross margin of 44.97% as per the latest financial report [1] Institutional Holdings - As of the first quarter of 2025, five institutions hold shares in Huaxia Eye Hospital, all being funds, with a total holding of 3.5318 million shares valued at 6.8 million yuan [1]

Core Viewpoint - The AMAC Resident Services Index has shown significant growth, with a year-to-date increase of 7.13%, indicating a positive trend in the sector [1]. Group 1: Index Performance - The AMAC Resident Services Index rose by 1.62% to 16,699.22 points, with a trading volume of 8.395 billion yuan [1]. - Over the past month, the index has increased by 6.03%, and over the last three months, it has risen by 4.09% [1]. Group 2: Index Composition - The AMAC Resident Services Index is composed of 43 industry classification indices, including 16 categories (excluding manufacturing) and 27 subcategories within manufacturing [1]. - The top ten holdings in the AMAC Resident Services Index are: Aier Eye Hospital (38.18%), Meien Health (10.37%), Tongce Medical (9.11%), Kingmed Diagnostics (5.38%), International Medical (5.35%), Sanbo Brain Science (5.22%), Dean Diagnostics (5.07%), Innovation Medical (3.65%), Huaxia Eye Hospital (3.32%), and New Mileage (2.85%) [1]. Group 3: Market Distribution - The market distribution of the AMAC Resident Services Index shows that 83.84% of the holdings are from the Shenzhen Stock Exchange, while 16.16% are from the Shanghai Stock Exchange [1]. - The sample holdings of the AMAC Resident Services Index are entirely within the pharmaceutical and healthcare sector, indicating a focused investment strategy [2].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [35]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.84% from August 4 to August 8, 2025, ranking 31st among 31 sectors and underperforming the CSI 300 index by 2.07 percentage points. The current PE valuation for the sector stands at 30.83 times, which is at the historical median level, with a valuation premium of 144% compared to the CSI 300 index [3][11][18]. - The report highlights the strong performance of the medical device sub-sector, which increased by 2.70%, while other sub-sectors such as biological products and pharmaceutical commerce saw declines [3][11]. - A total of 176 stocks in the sector rose (37.13%), while 287 stocks fell (60.55%) during the same period, with notable gainers including Nanmo Biology (42.48%) and Haichen Pharmaceutical (41.29%) [3][24]. Market Performance - The pharmaceutical and biotechnology sector has shown a year-to-date increase of 21.28%, ranking 5th among 31 sectors and outperforming the CSI 300 index by 16.96 percentage points. All sub-sectors have recorded gains, with chemical pharmaceuticals leading at 38.55% [14][19]. - As of August 8, 2025, the PE valuations for various sub-sectors are as follows: biological products at 38.25 times, chemical pharmaceuticals at 36.08 times, and medical devices at 33.29 times [18][27]. Industry News - Recently, seven government departments, including the Ministry of Industry and Information Technology and the National Health Commission, released a document aimed at promoting the innovation and development of the brain-computer interface industry. The plan outlines goals for technological breakthroughs by 2027 and the establishment of a reliable industrial system by 2030 [4][26][28]. - The report emphasizes the potential of brain-computer interfaces to revolutionize the integration of biological and machine intelligence, with significant policy support expected to accelerate industry growth [4][33]. Investment Recommendations - The report suggests focusing on the medical device sector and companies related to brain-computer interfaces, as well as high-quality stocks in innovative drugs, CXO, medical services, and second-class vaccines [4][33]. - Recommended stocks include Betta Pharmaceuticals, Teva Biopharmaceuticals, Kaili Medical, Anjies, and Huaxia Eye Hospital, with additional attention to stocks like Kelun Pharmaceutical and Qianhong Pharmaceutical [5][33].